Search results
Your search for process/pmg6 returned no results
Showing 421 to 435 of 2854 results for process
Showing 421 to 435 of 2854 results for process
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]
Awaiting development Reference number: GID-TA10797 Expected publication date: TBC
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
This quality standard covers diagnosing and managing type 1 and type 2 diabetes in children and young people (under 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS125Show all sections
Sections for QS125
- Quality statements
- Quality statement 1: Same-day referral and appointments
- Quality statement 2: Education and information
- Quality statement 3: Intensive insulin therapy and level 3 carbohydrate-counting education for type 1 diabetes
- Quality statement 4: Continuous glucose monitoring in type 1 diabetes
- Quality statement 5: Blood ketone monitoring in type 1 diabetes
- Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes
- Update information
In development Reference number: GID-NG10465 Expected publication date: TBC
This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.
NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable in adults. This is because Merck Sharp & Dohme did not provide a complete evidence submission.
Show all sections
Sections for TA674
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development Reference number: GID-TA10249 Expected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development Reference number: GID-TA10251 Expected publication date: TBC
In development Reference number: GID-TA10248 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
In development Reference number: GID-TA10223 Expected publication date: TBC
In development Reference number: GID-TA10227 Expected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]
In development Reference number: GID-TA10313 Expected publication date: TBC